Jpmorgan Chase & CO Veracyte, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.27 Trillion
  • Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Veracyte, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 93,867 shares of VCYT stock, worth $3.34 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
93,867
Previous 434,971 78.42%
Holding current value
$3.34 Million
Previous $17.2 Million 83.84%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 12, 2025
SELL
$29.65 - $46.14 $10.1 Million - $15.7 Million
-341,104 Reduced 78.42%
93,867 $2.78 Million
Q4 2024

Feb 12, 2025
BUY
$31.92 - $44.4 $2.82 Million - $3.92 Million
88,384 Added 25.5%
434,971 $17.2 Million
Q3 2024

Dec 26, 2024
SELL
$21.0 - $35.25 $53,403 - $89,640
-2,543 Reduced 0.73%
346,587 $11.8 Million
Q3 2024

Nov 08, 2024
SELL
$21.0 - $35.25 $53,403 - $89,640
-2,543 Reduced 0.73%
346,587 $11.8 Million
Q2 2024

Dec 26, 2024
BUY
$18.86 - $23.55 $47,960 - $59,887
2,543 Added 0.73%
349,130 $7.57 Million
Q2 2024

Aug 12, 2024
BUY
$18.86 - $23.55 $5.06 Million - $6.32 Million
268,466 Added 332.82%
349,130 $7.57 Million
Q1 2024

Dec 26, 2024
SELL
$21.0 - $29.1 $5.58 Million - $7.74 Million
-265,923 Reduced 76.73%
80,664 $1.79 Million
Q1 2024

May 10, 2024
SELL
$21.0 - $29.1 $768,159 - $1.06 Million
-36,579 Reduced 31.2%
80,664 $1.79 Million
Q4 2023

Dec 26, 2024
SELL
$19.72 - $28.68 $4.52 Million - $6.58 Million
-229,344 Reduced 66.17%
117,243 $3.23 Million
Q4 2023

Feb 12, 2024
SELL
$19.72 - $28.68 $2.83 Million - $4.12 Million
-143,623 Reduced 55.06%
117,243 $3.23 Million
Q3 2023

Nov 14, 2023
SELL
$22.33 - $29.92 $180,046 - $241,244
-8,063 Reduced 3.0%
260,866 $5.83 Million
Q2 2023

Aug 11, 2023
BUY
$20.96 - $26.99 $3.69 Million - $4.76 Million
176,275 Added 190.25%
268,929 $6.85 Million
Q1 2023

May 18, 2023
BUY
$20.58 - $27.89 $1.85 Million - $2.51 Million
90,034 Added 3436.41%
92,654 $2.07 Million
Q1 2023

May 11, 2023
SELL
$20.58 - $27.89 $7.88 Million - $10.7 Million
-382,829 Reduced 99.32%
2,620 $58,000
Q4 2022

Feb 13, 2023
BUY
$15.31 - $29.94 $937,125 - $1.83 Million
61,210 Added 18.88%
385,449 $9.15 Million
Q3 2022

Nov 14, 2022
BUY
$16.58 - $27.9 $4.26 Million - $7.17 Million
256,867 Added 381.27%
324,239 $5.38 Million
Q2 2022

Aug 11, 2022
BUY
$15.45 - $29.52 $186,203 - $355,775
12,052 Added 21.79%
67,372 $1.34 Million
Q1 2022

May 11, 2022
BUY
$21.94 - $42.51 $210,382 - $407,628
9,589 Added 20.97%
55,320 $1.53 Million
Q4 2021

Feb 10, 2022
BUY
$36.09 - $53.79 $75,572 - $112,636
2,094 Added 4.8%
45,731 $1.88 Million
Q3 2021

Nov 12, 2021
BUY
$35.62 - $52.97 $1.55 Million - $2.31 Million
43,637 New
43,637 $2.03 Million

Others Institutions Holding VCYT

# of Institutions
295
Shares Held
77.2M
Call Options Held
0
Put Options Held
17.6K
View Full List

About VERACYTE, INC.

VCYT Quotes by TradingView
  • Ticker VCYT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,575,904
  • Market Cap $2.55B
  • Description
  • Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...
More about VCYT
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email